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Leukocyte cell-derived chemotaxin 2 (Lect2) is a chemokine-like chemotactic factor 
that has been identified as a downstream target of the Wnt signalling pathway.  
Whilst the primary function of Lect2 is thought to be in modulating the inflammatory 
process, it has recently been implicated as a potential inhibitor of the Wnt pathway. 
Deregulation of the Wnt pathway, often due to loss of the negative regulator APC, is 
found in ~80% of colorectal cancer (CRC).  Here we have used the ApcMin/+Lect2-/- 
mouse model to characterise the role of Lect2 in Wnt-driven intestinal 
tumourigenesis. Histopathological, immunohistochemical, PCR and flow cytometry 
analysis were employed to identify the role of Lect2 in the intestine.  The 
ApcMin/+Lect2-/- mice had a reduced mean survival and a significantly increased 
number of adenomas in the small intestine with increased severity.  Analysis of Lect2 
loss indicated it had no effect on the Wnt pathway in the intestine but significant 
differences were observed in circulating inflammatory markers, CD4+ T cells, and T 
cell lineage-specification factors.  In summary, in the murine intestine loss of Lect2 
promotes the initiation and progression of Wnt-driven colorectal cancer.  This 
protection is performed independently of the Wnt signalling pathway and is 












The progression of colorectal cancer (CRC) from a benign to a malignant state is a 
multi-stage process that requires key changes in both oncogenes and tumour 
suppressor genes. A critical pathway in the pathogenesis of CRC is the Wnt 
signaling pathway and inactivation of APC or activating mutations in β-catenin are 
found in the majority of patients presenting with CRC[1].  It is therefore not surprising 
that the Wnt pathway and its downstream mediators are attractive targets for new 
therapeutics and several small molecule inhibitors and natural compounds have 
been identified to have potential therapeutic value against Wnt-driven tumorigenesis 
through either direct or indirect mechanisms[2]. 
Leukocyte cell-derived chemotaxin 2 (Lect2) is a chemokine-like chemotactic 
factor that has been identified as a downstream target of the Wnt signalling 
pathway[3, 4]. Lect2 has a key role in several pathological conditions including 
rheumatoid arthritis[5, 6], renal amyloidosis[7], hepatocellular carcinoma[3], liver 
injury[5] and sepsis[8], where its main activity is thought to be in modulating the 
inflammatory response. In the liver, Lect2 has a protective anti-inflammatory role in 
β-catenin-induced tumorigenesis and loss of this chemokine results in tumour 
progression and metastatic disease[3].  Previous studies have implicated Lect2 as a 
potential inhibitor of the Wnt pathway and Lect2 has been hypothesised to play a key 
role in the inhibition of intestinal tumorigenesis observed in the ApcMin/+Mbd2-/- mouse 
model due to this inhibitory effect on Wnt signalling[4]. Whilst the precise function 
and mechanism of Lect2 in the development of CRC is still unclear, the potential of 
this molecule as a regulator of the Wnt pathway warrants further investigation. In 
addition, the role of Lect2 in inflammation and the potential of this chemokine to 
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affect intestinal tumour development by altering the inflammatory response is of 
significant interest and may aid the identification of novel targets in the treatment of 
this disease. 
Therefore, to investigate the role of Lect2 in Wnt-driven intestinal 
tumorigenesis, we generated an ApcMin/+Lect2-/- mouse model. Our study 
demonstrates that loss of Lect2 in the ApcMin/+ mouse had a significant pro-
tumorigenic effect, confirming a protective tumour suppressor role for Lect2 in Wnt-






















MATERIALS AND METHODS 
Experimental mice.  
Animals were maintained on an outbred background, housed in a standard facility 
and all experimental procedures were performed in accordance with institutional 
animal care and ARRIVE guidelines in compliance with UK Home Office regulations. 
In brief, mice were maintained in conventional open top cages on dust free bedding 
(IPS Ltd) under a 12hr light cycle, with RM3(E) diet (Special Diet Services UK) 
provided for nutritional support. To enrich the environment, sunflower seeds (at 
weaning only, LBS Ltd), nestlets (IPS Ltd), disposable envirotubes (IPS Ltd) and 
small chewsticks (Labdiet‐IPS Ltd) were provided. Mice carrying the targeted Lect2 
allele were kindly supplied by Dr Satoshi Yamagoe [5]. Experimental mice were 
genotyped as previously described for the targeted Lect2 allele[5], Apc allele[9], the 
ApcMin/+ allele[10], the Rosa26R allele[11] and the AhCre transgene[12]. Cre activity 
was induced in control and experimental mice by 3 consecutive intraperitoneal (i.p.) 
injections of 80mg/kg β-naphthoflavone (Sigma, UK) in 24h. Mixed sex control (litter 
mates) and experimental mice were used for timepoint (N>4) or survival (N>15) 
experiments.  Prior to proliferation analysis selected animals were injected with 
100μg/kg Bromo-deoxyuridine (Sigma, UK) and culled at indicated time points after 
labelling.  
 
Histology and Immunohistochemistry.  
Intestinal tissue was fixed, processed and haematoxylin and eosin stained as 
described previously[13].  The following antibodies were used for 
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immunohistochemistry: anti-Cd4(1:100; eBioscience), anti-Cd8 (1:200; eBioscience) 
anti-Caspase 3 (1:750; R&D systems), anti-β-catenin (1/50; Becton Dickinson), anti-
Ki67 (1:200; Vector Labs) and mouse anti-BrdU (1:100; Becton Dickinson).  Staining 
for Treg cells was performed on a Ventana (Roche) Discovery Ultra Autostainer 
(Serial number 313108) using Antigen Retrieval CC1 buffer (Ventana) for 48 minutes 




Cellular analysis was performed on >25 whole crypts from at least three mice of 
each genotype. Apoptotic and mitotic index were scored from haematoxylin-and-
eosin-stained sections as previously described (36). The cells between the base of 
the crypt and the junction with the villus was designated as the proliferative zone.  
For migration analysis mice of 60-80 days of age were given an IP injection of BrDU 
2hours or 24hours prior to culling and dissection. Immunohistochemical analysis for 
BrDU incorporation was performed on formalin fixed small intestinal rolls, and the 
number BrDU positive cells and their location (with 0 being the bottom of the crypt) 
was measured on 50 half-crypts per mouse, minimum of 4 mice. Statistical analysis 
of the cumulative frequency of positive cells was performed using a two-tailed 
Kolmogorov-Smirnov test, on graphs P values are indicated as follows: ∗P < 0.05; 
∗∗P < 0.01; ∗∗∗P <0 .001. 
 
Quantitative real-time RT-PCR 
Total RNA was isolated from tissues using a standard Trizol protocol and DNAse 
treatment was carried out using the Turbo DNA-free kit (Life Technologies Ltd., UK). 
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One microgram of RNA was reverse transcribed using Superscript III according to 
the manufacturer’s protocol (Life Technologies Ltd., UK). Gene expression analysis 
was carried out using either TaqMan Universal PCR mastermix or Fast Sybr green 
mastermix according to the manufacturer’s protocol (Life technologies Ltd., UK). The 
primer sequences used in the PCR reactions available upon request. Primers and 
TaqMan probes specific for Lgr5, IL-4, IFN-gamma, TNF-alpha, FoxP3 and B-actin 
were obtained from Taqman gene expression assays (Life Technologies Ltd., UK). 
Data analysis was carried out using StepOne™ Software v2.2.2 (Life Technologies 
Ltd., UK). Relative expression levels of target genes were calculated using the 
comparative cycle threshold (Ct) method as described previously[14]. The values for 
β-actin were used to normalize the gene expression data. The gene expression 
levels in intestinal tumours relative to the control intestinal normal tissues were 




The levels of serum IFN-γ, TNF-α, IL-10, IL-6, IL-4, and IL-17a were quantified using 
the BD Cytometric Bead Array mouse Th1/Th2/Th17 Cytokine kit (BD Pharmingen, 
Oxford, UK). 
 
Flow cytometric analysis 
Single cell suspensions from the liver and the spleen were incubated with 
monoclonal antibodies against cell surface markers (BD Pharmingen, Oxford, UK). 
APC- and FITC- conjugated antibodies specific for CD3 (145-2C11), CD4 (RM4-5), 
NK1.1 (PK136), CD11b (M1/70), Gr-1 (RB6-8C5), Mac-1/Cd11b (M1/70) were used 
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for flow cytometric analysis. Resident monocytes were identified as CD11b+Gr-1- 




Loss of Lect2 modifies Wnt-driven tumourigenesis and reduces survival.  
Lect2 has been implicated as a novel Wnt repressor and a potential tumour 
suppressor in CRC[4]. In order to test this hypothesis we crossed the Lect2-/- allele[5] 
onto an ApcMin/+ background. The ApcMin/+ mouse model is a well-established CRC 
model that is heterozygous for a mutation in the Apc gene and develops multiple 
intestinal neoplasia. Cohorts of at least 15 experimental and control mice were aged 
and the mice were monitored regularly for signs of intestinal tumours (rectal 
bleeding, prolapse, anaemia) or other illness and were taken for analysis when they 
became symptomatic of disease. Comparison of the endpoint demonstrated the 
mean survival of ApcMin/+Lect2-/- (239 days; N=23) was significantly shorter than in 
the control ApcMin/+Lect2+/+ (308 days; N=19) cohort (Log-rank (Mantel-Cox) test, 
P=0.042) (Figure 1A).  All cohorts developed adenomas within the small intestine 
and the large intestine, with no other Apc+/min associated clinical phenotypes 
observed. The decrease in survival of ApcMin/+Lect2-/- mice correlated with a 
significantly increased number of adenomas in the small intestine compared to the 
ApcMin/+Lect2+/+ mice at death (mean of 26.8 tumours versus 15.2 tumours, Mann 
Whitney U-test, P=0.0138; Figure 1B).  No significant difference was seen in the 
number of adenomas in the large intestine.  By contrast, a significant reduction in 
mean tumour size was observed in the ApcMin/+Lect2-/- cohort, both in the small (5.6 
mm2 versus 8.9 mm2, Mann Whitney U-test, P=0.0001) and large (7.1 mm2 versus 
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9.2 mm2, Mann Whitney U-test, P=0.0038) intestine (Figure 1C).  As further analysis 
of intestinal tumour burden at survival endpoint (Figure 1D) indicated no significant 
difference between cohorts the reduction of mean tumour size in the ApcMin/+Lect2-/- 
is likely a reflection of the animals’ shortened longevity. 
As we previously identified upregulation of Lect2 the tumour suppression observed in 
the ApcMin/+Mbd2-/- [4] we generated ApcMin/+Mbd2-/-Lect2-/- to clarify its role in this 
phenotype.  However, the additional loss of Lect2 failed to reverse the suppression 
of tumour initiation observed in the ApcMin/+Mbd2-/- mice (Supplementary Figure 
1A&B) indicating Lect2 does not play a significant role in the suppression of intestinal 
tumourigenesis observed in that model. 
In summary this data indicates that Lect2 plays a role in preventing tumour initiation 
in the ApcMin/+intestine. 
 
Lect2 status influences tumour severity in the small intestine. 
To gain a clearer understanding of the decrease in survival seen in the ApcMin/+Lect2-
/- cohort and to fully characterise the effect of Lect2 loss on the ApcMin/+ phenotype 
we histologically characterised the small intestine and the large intestine tumours of 
both the ApcMin/+Lect2+/+ and the ApcMin/+Lect2-/- cohorts.  Tumours were classified as 
microadenomas (T1); adenomas (T2); early invasive adenocarcinomas showing 
invasion into the submucosa but not the muscularis propria (T3); and advanced 
invasive adenocarcinoma that penetrated into or through the muscularis propria (T4). 
The control (ApcMin/+Lect2+/+) mice had benign microadenomas T1 (Figure 2A & B; 
n=13/13; 100%) and T2 adenomas (n=12/13; 92.3%), with rare T3 adenocarcinomas 
(n=1/13; 7.7%) or T4 tumours invading into the muscularis propria (n=1/13; 7.7%; 
Figure 2B). The ApcMin/+Lect2-/- displayed a significant shift in progression with a 
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reduction in the percentage of mice with early T1 lesions to 72.8% (n=8/11) with a 
corresponding increase in early invasive T3 lesions to 36.4% (n=4/11) (Chi-Squared 
Test P<0.0001; Figure 2B).  To understand whether progression was due to 
alteration in cell homeostasis we next performed immunohistochemical analysis for 
Ki67, a marker of proliferation, and cleaved Caspase-3, a marker of apoptosis. The 
percentage of positively-staining cells in tumours of both the ApcMin/+Lect2+/+ (N=4) 
and ApcMin/+Lect2-/- (N=5) cohorts indicated that loss of Lect2 had no significant 
effect on either cell proliferation (Figure 2C) or cell death (Figure 2D) in our Wnt-
driven tumours.  To address the Wnt-inhibitory function of Lect2 we used qRT-PCR 
analysis to compare the expression of Wnt targets in tissue isolated from the 
ApcMin/+Lect2+/+ (N=4) and ApcMin/+Lect2-/- (N=4) cohorts. Whilst we were able to 
show the previously characterised induction of downstream Wnt targets during Wnt-
driven tumorigenesis, the additional loss of Lect2 had no significant effect on the 
expression of key Wnt target genes (Figure 2H).  Taken together this indicates that 
the homozygous loss of Lect2 enhances tumour initiation and progression in the 
ApcMin/+ model independently of an effect on the Wnt pathway. 
 
Loss of Lect2 does not modify the activated-Wnt signature in the small 
intestine. 
As our data shows that Lect2 modulates Wnt-driven tumorigenesis, but does not 
appear to directly effect Wnt-signalling in developed tumours we next addressed 
whether Lect2 may have a key role during the very early stages of Wnt-activation.  
We crossed the Lect2-/- allele onto a conditional Apc background[16] and analysed 
the effect of Lect2 deficiency in the context of acute Wnt signalling following Apc 
loss. Cre activity was induced in both the AhCre+Apcfl/flLect2-/- and 
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AhCre+Apcfl/flLect2+/+ mice by intraperitoneal injection of β-naphthoflavone. Previous 
studies have demonstrated that three injections of 80mg/kg of β-naphthoflavone in 
24hrs results in efficient (~100%) recombination of the Apc allele[17] in the mouse 
small intestine. Due to the previously reported[16] overt phenotype of induced 
AhCre+Apcfl/flLect2+/+ mice both experimental and control cohorts were killed at day 5 
post-induction (PI) and the tissues analysed.  
qRT-PCR analysis of Lect2 expression in the AhCre+Apcfl/fl confirmed Lect2 
as a downstream target of Wnt signalling in the mouse small intestine (Mann-
Whitney P=0.0286; N=4v4) and loss of Lect2 expression in our experimental 
AhCre+Apcfl/flLect2-/- cohort (Mann-Whitney P=0.0286; N=4v4) (Figure 3A). To 
assess the phenotypic consequences of the deletion of both Apc and Lect2 we 
analysed the crypt-villus structure.  The number of cells per crypt were scored from 
haematoxylin and eosin-stained sections as described previously[13]. The data for 
the control mice (AhCre+Apc+/+Lect2+/+, AhCre+Apcfl/flLect2+/+; Figure 3B) at day 5 PI 
were consistent with previous data[13].  With a significant increase in crypt cell 
number between the wild-type and AhCre+Apcfl/flLect2+/+ mice (n=4, Mann Whitney 
U-test P= 0.0304) (Figure 3B).  Additional loss of the Lect2 allele had no effect on 
either the wild-type (N=4, Mann Whitney U-test P= 0.3856) or the Apc homozygous 
phenotype (N=4, Mann Whitney U-test P= 0.6650).  In addition to quantifying crypt 
cell number, apoptosis and mitosis were scored as described previously[13]. The 
data for the control mice (AhCre+Apc+/+Lect2+/+, AhCre+Apcfl/flLect2+/+; Figure 3C&D) 
at day 5 PI were consistent with previous reports[13] with a significant increase in 
mitosis and apoptosis between the AhCre+Apcfl/flLect2+/+ (Mann Whitney U-test, 
P=0.0404) and wild-type mice, with no significant effect of Lect2 deletion (Figure 3C 
& D). In addition we analysed the localisation of the Paneth cells in our mouse 
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models.  Paneth cell localisation is altered in the Apc homozygous mice[16] and 
previous studies using the AhCre+Apcfl/flMbd2-/- mice, where Lect2 expression was 
shown to be upregulated, demonstrated a significant reduction in the mislocalisation 
of this cell population[4]. The expected mislocalisation of lysozyme-positive cells 
along the length of the aberrant crypt-villus axis was confirmed in the Apc 
homozygous mice, and Lect2 loss had no further significant effect, either in the wild-
type or Apc homozygous cohorts (Supplementary Figure 2A).  
To further characterise the effect of Lect2 on the Wnt signalling pathway in 
our short-term Apc homozygous model, we used qRT-PCR analysis to compare the 
expression of Wnt targets in tissue isolated from control and experimental cohorts. 
Whilst we demonstrated the previously characterised induction of downstream Wnt 
targets, due to Apc loss, the additional loss of Lect2 in either the AhCre+Apc+/+Lect2-
/- or the AhCre+Apcfl/flLect2-/- mice had no significant effect on the expression of key 
Wnt targets in the small intestine (Figure 3E).  In summary the loss of Lect2 has no 
impact on cell homeostasis or Wnt activity in the intestine. 
 
Lect2 has a role in regulating the circulating levels of key inflammatory 
markers. 
The above data argues that the observed modulation of Wnt-driven tumorigenesis by 
the absence of Lect2 does not appear to be due to a cell autonomous role for Lect2 
in regulating Wnt signaling. We have therefore explored other possible mechanisms 
for Lect2 action. Several studies have shown that, similar to other solid 
malignancies, colorectal tumours demonstrate inflammatory infiltration with multiple 
cell types that may have pro- or anti-tumorigenic role[18]. In addition, recent work by 
McClellan et al[19] has demonstrated that the activation of key inflammatory 
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mediators in a Wnt-activated CRC model produces a microenvironment that has an 
important impact upon tumoral development in the intestine. Lect2 is a chemokine 
and has been shown to have a key role in the inflammatory response in β-catenin-
induced liver tumorigenesis where it is associated with a suppressive effect on 
inflammation-related cytokine production[3]. In order to analyse whether the tumour 
suppressor function of Lect2 in Wnt-driven tumorigenesis is due to its role in 
inflammation we measured key cytokine levels in our Wnt-activated models of CRC. 
We analysed serum from our AhCre+Apc+/+ (N=5), AhCre+Apcfl/+Lect2+/+ (N=5) and 
AhCre+Apcfl/+Lect2-/- (N=5) at day 55 PI. The AhCre+Apcfl/+ tumour model was used 
in our short-term cohorts as this model develops tumours at a similar latency to that 
of the ApcMin/+ model, inducing Apc deletion at a fixed time point provides 
experimental consistency and Apc  remains intact within the immune system.  
Samples from day 55 PI were analysed in order to investigate the effect of Wnt-
activation and Lect2 loss on cytokine expression prior to tumour development.  
At day 55 PI, Apc heterozygosity did not alter the circulating levels of several 
cytokines compared to wild-type mice (Figure 4). In contrast, Lect2 deficiency in this 
model resulted in a significant decrease in IL-10 (AhCre+Apcfl/+Lect2-/- versus 
AhCre+Apcfl/+Lect2+/+; median concentration 31.75 pg/ml versus 87.49 pg/ml; 
P=0.0404; Figure 4A), IL-17a (AhCre+Apcfl/+Lect2-/- versus AhCre+Apcfl/+Lect2+/+; 
median concentration 1.08 pg/ml versus 6.05 pg/ml; P=0.0404; Figure 4B), TNF-α 
(AhCre+Apcfl/+Lect2-/- versus AhCre+Apcfl/+Lect2+/+; median concentration 4.74 pg/ml 
versus 27.34 pg/ml;P=0.0404; Figure 4C) and IL-6 (AhCre+Apcfl/+Lect2-/- versus 
AhCre+Apcfl/+Lect2+/+; median concentration 2.51 pg/ml versus 71.19 pg/ml; 
P=0.0404; Figure 4D).  In addition several other key cytokines showed trends 
towards a decrease in their levels although this was not significant, such as IFN-γ 
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(AhCre+Apcfl/+Lect2-/- versus AhCre+Apcfl/+Lect2+/+; median concentration 4.11 pg/ml 
versus 8.68 pg/ml; P=0.1914; Figure 4E), IL-4 (AhCre+Apcfl/+Lect2-/- versus 
AhCre+Apcfl/+Lect2+/+; median concentration 0.66 pg/ml versus 1.26 pg/ml; 
P=0.3313; Figure 4F) and IL-2 (AhCre+Apcfl/+Lect2-/- versus AhCre+Apcfl/+Lect2+/+; 
median concentration 1.62 pg/ml versus 6.73 pg/ml; P=0.0952; Figure 4G). This 
trend towards a global reduction cytokine levels indicates that Lect2 plays a role in 
driving or maintaining the inflammatory response that occurs in the presence of Wnt 
driven intestinal tumours. 
 
Lect2 deficiency increases the proportion of CD4+ T cells in the spleen. 
Previous studies have identified a key role for Lect2 in the regulation of 
specific sub-populations of inflammatory cells and this function was key to the 
tumour suppressor role of Lect2 in β-catenin-activated HCC[3].  To evaluate whether 
the ability of Lect2 to alter the cytokine levels was related to an alteration in immune 
cell populations we measured the proportions of immune cells in the liver and the 
spleen at day 55 PI by FACS. Analysis of proportions of neutrophils, monocytes and 
total mononuclear cells, in both these models indicated no significant changes due to 
Lect2 loss (Figure 5A, B, D & E and Supplementary Figure 3A&C).  However, we did 
show a significant increase in the proportion of monocytes in the spleen of 
AhCre+Apcfl/+Lect2+/+ mice compared to wild-type (2.2% versus 1.2%; two-tailed t test 
on Log10 transformed data, P=0.031; Figure 5E).  Further analysis of the proportions 
of NK cells, NKT cells, conventional CD3+ T cells and CD4+ NKT cells in both the 
spleen and the liver and found no significant differences in either model 
(Supplementary Figure 3A-J).  However, the analysis of CD4+T cells in the spleen of 
our AhCre+Apcfl/+Lect2-/- mice identified a small but significant increase compared to 
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the AhCre+Apcfl/+Lect2+/+ model (18.2% versus 15.6%; two-tailed t test on Log10 
transformed data, P=0.010; Figure 5F).  Although no such difference was observed 
in the liver (Figure 5C).  This data combined with the cytokine alterations (Figure 3) 
identified potentially indicates a role for Lect2 in maintaining a tumour suppressive 
immune intestinal microenvironment. 
 
Lect2 deficiency influences Treg cells in the loss of Lect2 influences the  
To understand the relationship between the widespread deregulation of circulating 
cytokines and proportional increase in splenic CD4+ T cells in the 
AhCre+Apcfl/+Lect2-/- mice we analysed the expression of key transcription factors 
that regulate cytokine expression and T cell differentiation. Several master 
transcription factors have been identified which regulate T cell fate and cytokine 
expression during tumourigenesis[20, 21] and the activity of these regulators is 
primarily determined by their expression levels. Therefore, using qRT-PCR we 
analysed the expression of Gata-3, T-bet, FoxP3, Bcl-6 and Runx3, all of which 
function as part of a network to regulate the inflammatory response. The expression 
of these transcription factors was analysed in the spleens of both the 
AhCre+Apcfl/+Lect2+/+ (N=4) and the AhCre+Apcfl/+Lect2-/- (N=4) cohorts at day 55 PI 
(Figure 6A). Interestingly Gata-3 (2.99-fold up-regulation; P=0.0428), FoxP3 (5.86-
fold up-regulation; P=0.0214) and RunX3 (4.48-fold up-regulation; P=0.0142) all 
showed a significant increase in the AhCre+Apcfl/+Lect2+/+ mice compared to wild-
type (Figure 6A), and both GATA-3 and FoxP3 were further increased in the 
AhCre+Apcfl/+Lect2-/- model (1.8- and 3.5-fold respectively; P=0.0051 and P=0.0025). 
The expression of both T-bet and Bcl-6 showed no significant change in either 
model. The Lect2 dependent increase in Gata-3 and FoxP3 indicated a role for the 
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immune suppressive CD4+ Treg cell population[22].  Foxp3 is a marker of CD4+ 
immunosuppressive Treg cells, which could suppress an anti-cancer immune 
response and are associated with tumour progression[23].  To address whether the 
altered expression of the lineage factors was reflected in the numbers of immune 
cells within the tumours we quantified the numbers of CD4+, CD8+ and Treg cells in 
splenic tissue and intestinal tissue using immunohistochemical staining (number of 
was based on the average number of cells in 5 sequential longitudinal sections taken 
every 100m).  Immunohistochemical analysis of the groups indicated no overall 
difference density of CD4+ or CD8+ between polyps from ApcMin/+Lect2+/+ and 
ApcMin/+Lect2-/- cohorts (Figure 6 B&C).  The major alteration identified was a 
significant increase in the density of CD8+ cells, but not CD4+, in T1 tumours from 
ApcMin/+Lect2-/- mice, the stage significantly decreased in this model (Figure 6 D&E).  
Subsequent analysis of CD4+FoxP3+ Treg cells indicated no significant difference in 
the spleen and a non-significant trend towards an increase in the intestine (Figure 
6F; ApcMin/+Lect2-/-(N=4) and ApcMin/+Lect2+/+(N=5)). Thus, the increase in FoxP3 
expression observed in the spleen is likely due to it being upregulated within the in 
situ Treg cells.  While not conclusive, the trend towards an increased number of 
Tregs in the intestine supports the premise that the increase in number and 
progression of Wnt driven tumours in the Apcmin/+Lect2-/- tumour progression is 
















Whilst the inhibition of the Wnt signalling pathway is thought to have clear 
therapeutic potential in the treatment of CRC, the complexity of this signalling 
cascade has hindered the development of targeted treatment for this disease. 
Therefore, a clearer understanding of this signalling pathway, through the 
identification of key regulatory proteins and important downstream targets of β-
catenin will significantly improve the development of treatments for Wnt-driven 
tumorigenesis. Lect2 is a downstream target of the Wnt pathway and has a key role 
in inflammation, although its precise mechanism of action in vivo is still unclear. In 
the liver Lect2 has been shown to have a protective anti-inflammatory role in β-
catenin-induced tumorigenesis[3] and the role of Lect2 as a tumour suppressor in 
human HCC has been firmly established[24].  Lect2 has also been shown to be a 
downstream target of the Wnt pathway in the intestine and has been hypothesised to 
have a protective role during Wnt-driven tumorigenesis[4].  
Our previous studies investigating the role of the methyl binding protein Mbd2 
in Wnt-driven CRC identified Lect2 as a downstream target of the Wnt pathway in 
the intestine and demonstrated a key role for Lect2 as a Wnt inhibitor[4]. To confirm 
and further investigate the function of Lect2 in Wnt-driven CRC, we homozygously 
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deleted Lect2 in the ApcMin/+ mouse model. Using this model, we identified a novel 
role for Lect2 as a tumour suppressor in Wnt-driven intestinal tumorigenesis. Loss of 
Lect2 resulted in a significant decrease in survival in our ApcMin/+ mouse model, 
which was associated with a significant increase in adenoma number in the small 
intestine. In addition, the number of advanced tumour lesions was increased, despite 
the 30% reduction in the longevity of the mice, indicating that the homozygous loss 
of Lect2 enhances both Wnt-activated tumour initiation and progression, identifying a 
clear protective role for Lect2 in intestinal tumorigenesis. However, our data 
indicating the loss of Lect2 had no impact on the phenotype of the Apc+/minMbd2-/- 
mice suggests that epigenetic silencing of Lect2 doesn’t play a key role in intestinal 
tumour initiation but is more relevant to inflammation and tumour progression[25]. 
As Lect2 was previously indicated to function as a Wnt repressor we 
hypothesised that the tumour suppressor role of Lect2 may be due to a protective 
inhibitory function in the initiating stages of Wnt deregulation. Therefore, to 
investigate the effects of Lect2 loss on the Wnt signalling pathway we used an early-
stage Wnt-activated model to characterise the effect of Lect2 loss on the initial 
stages of aberrant Wnt signalling in the mouse small intestine. Our results 
demonstrate that whilst Lect2 is a downstream target of the Wnt pathway, 
homozygous loss of this tumour suppressor had no effect on the activated Wnt 
signature, indicating that the protective role of Lect2 may be independent of Wnt 
signalling in the mouse intestine. 
In addition to its potential role as a Wnt inhibitor Lect2 has been shown to 
have a key role in inflammation. Lect2 has a protective anti-inflammatory role in 
arthritis and in the liver Lect2 regulates the homeostasis of NKT cells and also the 
expression of IL-4 and IFN-γ[5]. Furthermore, Lect2 has been shown to be a 
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mediator of the β-catenin inflammatory response during hepatocellular carcinoma 
and loss of this tumour suppressor results an increase in tumorigenesis[3].  
Therefore, we investigated whether loss of Lect2 had an effect on the inflammatory 
response during colorectal tumorigenesis.  
Our results demonstrated that the loss of Lect2 in our Wnt-activated model 
significantly altered the levels of circulating cytokines. The effect was widespread 
with levels of both pro- and anti-inflammatory cytokines being suppressed upon the 
homozygous loss of Lect2, which was further seen in the local inflammatory 
environment of key tissues such as the spleen and the liver, although to a lesser 
extent in the small and large intestine. A similarly altered cytokine secretion profile in 
response to the loss of Lect2 has been previously shown in the liver and this altered 
profile in Lect2-/- mice was shown to be associated with an alteration in the profile of 
infiltrating immune cells[5, 26].  Thus, it seem that Lect2 loss is well tolerated but 
alters systemic inflammatory responses when aberrant oncogenic Wnt activation 
occurs in target organs.  This is possibly due to impaired barrier function with the 
host microbiome, in accordance with other data indicating that Ifng and TNF- 
production in NK and NKT cells is lower in Lect2-/- mice exposed to bacterial 
LPS[26].  It is well established that genetic alterations involved in driving 
tumorigenesis activate an inflammatory program that has a significant impact on 
tumour development[27] and several studies have highlighted the role of 
inflammation in CRC.  However, the exact role that each cytokine plays is clouded by 
conflicting data as to whether they are pro- or anti-tumourigenic (reviewed by Mager 
et al [28] and Chen and Zhou [29]. For example IL-10, which is reduced in the 
Apc+/flxLect2-/- mice, has been shown to be a key cytokine which when produced by 
Treg cells that can reduce tumour burden in the Apc+/min model [30, 31]. Despite the 
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Treg marker FoxP3 being increased in our models there was no increase in the 
number of Treg cells indicating that either Foxp3 upregulation inhibits they’re ability 
to produce Il-10 or it is due to dysfunction in other Il-10 producing cells such as 
macrophages, mast cells eosinophils and dendritic cells[32].  The Il-10 reduction is 
consistent with other studies that have shown that T cell-restricted ablation of IL-10 
increased the number of polyps by promoting the accumulation of microbes and 
eosinophils [33] and IL-10 deficient mice are more susceptible to spontaneous 
intestinal tumour development[34].  Therefore, in order to further investigate the role 
of Lect2 in the immune response during Wnt-driven tumorigenesis we characterised 
the subpopulations of inflammatory cells in both the spleen and liver. Our results 
show that the loss of Lect2 leads to a significant increase in the proportion of the 
CD4+ subpopulation of T cells in the spleen.   
CD4+ T cells carry out multiple functions, ranging from activation of the cells of 
the innate immune system, B-lymphocytes, cytotoxic T cells, as well as non-immune 
cells, and they also play critical roles in the suppression of the immune reaction. 
Subsets of CD4+ T cells include the classical Th1 and Th2 cells and differentiation of 
the different lineages depends on a complex network of specific cytokine signalling 
and lineage specific transcription factors. An imbalance of Th1 and Th2 cells is 
thought to be responsible for both the occurrence and also the progression of 
several diseases, and patients with advanced cancer often have impaired cell-
mediated immunity associated with a switch from Th1 to Th2[35, 36, 37]. Work by 
Anson et al.[3] demonstrated that loss of Lect2 significantly altered the inflammatory 
microenvironment by shifting the balance towards a Th2 pro-tumorigenic 
inflammatory program, which allowed tumour growth and progression. 
As the presence of CD4+ cells can be anti- or pro-tumourigenic depending on 
21 
 
the lineages present [38] we therefore investigated whether loss of Lect2 resulted in 
an alteration in the expression of key transcription factors required for the differential 
development of the antigen-activated CD4+ T cells. Our results demonstrate that loss 
of Lect2 significantly increased the expression of GATA-3 and FoxP3 in the spleen. 
GATA-3 is a Th2 master regulator that is critical for the development of CD4+ Th2 
cells, and FoxP3 expression is required for the generation of immune-suppressive 
CD4+CD25+ regulatory T cells (Tregs). GATA-3 also positively regulates FoxP3 
expression to regulate Treg cell function[39] and the Treg cell lineage is thought to 
inhibit the protective anticancer inflammatory response[23]. While we failed to see an 
increase in the number of Treg cells in our models the increase in FoxP3 expression 
may reflect an increase in their turnover or regulatory abilities. As it has been 
previously shown that mast cells, which accumulate in Apc+/min polyps and human 
colorectal cancer are linked to progressive polyp growth[40], as they interact with 
Treg cells to generate potently immune suppressive but pro-inflammatory FoxP3+ 
cells that are characterised by a reduction in IL-10 production[41], a feature 
observed in our model. In addition, outside the haemopoietic system, both FoxP3 
and GATA-3 have various roles in tumour development which may be pro- or anti-
tumorigenic, depending on the tumour type[42, 43].  
In conclusion, our data demonstrate a novel role for Lect2 as a tumour 
suppressor during Wnt-driven intestinal tumorigenesis. Whilst this role is 
independent of a direct effect on the Wnt pathway, our results indicate that Lect2 
functions as a mediator of the inflammatory response during Wnt activation in the 
intestine and the loss of this chemokine alters the balance of both pro and anti-
inflammatory cytokines and key regulators of T cell lineages. This alteration in T cell 
regulators may alter CD4+ T cell subsets and disrupt the immune environment, 
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promoting tumour growth, although further studies are required to confirm this. 
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Figure 1: Homozygous Lect2 deletion drives Wnt-driven tumorigenesis and 
decreases survival. (A) Kaplan-Meier survival analysis indicating a decrease in 
survival of the experimental Apc+/minLect2-/- (N=23) mice compared to the control 
Apc+/minLect2+/+(N=19) cohort (Log-rank (Mantel-Cox) test, P=0.042).  Formalin fixed 
tissue was used to quantify small (SI) and large (LI) intestine tumour number (B), 
size (C) and burden (D) at time of death. Indicating an increase in number of small 
intestine tumours in Apcmin/+Lect2-/- mice (B; Mann-Whitney P=0.0138) with a 
corresponding decrease in tumour size in the small (P=0.0001) and large (P=0.0038) 
intestine(C).  Overall burden was unaltered at death (D) due to the increase in 
number of tumours compensating for their reduced size due to reduced longevity. 
 
Figure 2: Loss of Lect2 accelerates Wnt-activated tumour progression. 
Histological examination of small intestine tumours from both ApcMin/+Lect2+/+ (A; 
microadenoma) and ApcMin/+Lect2-/- (B; microadenoma) mice (Bar 50m). (C) 
Classification of tumour grades from ApcMin/+Lect2+/+ (N=19) and ApcMin/+Lect2-/- 
(N=23) mice.  Demonstrating an increase in overall severity upon Lect2 loss (Chi-
28 
 
Squared Test P<0.0001) with a decrease in T1 and increase in T3 lesions (Chi-
Squared Test P<0.0001). Tissue sections from ApcMin/+Lect2+/+ (N=4) and 
ApcMin/+Lect2-/- (N=4) mice were stained with antibodies detecting proliferation 
marker  Ki67 (D) and apoptosis marker cleaved-Caspase 3 (E).  Quantification of by 
scoring positively-stained cells in ten fields of view per tumour indicated no 
significant changes.  (F) qRT-PCR analysis of down-stream Wnt-targets. The data 
shown is in terms of the dC(t) values used to calculate the ddC(t) fold-change 
values. 
 
Figure 3: Combined loss of Apc and Lect2 in the mouse small intestine has no 
significant effect on the Apc homozygous phenotype. (A) qRT-PCR analysis of 
Lect2 expression 4 days following deletion of Apc. The data shown is in terms of the 
dC(t) values used to calculate the ddC(t) fold-change values. Analysis of crypt cell 
number (B), mitosis (C) and apoptosis(D) from H&E-stained histological sections of 
mouse small intestine indicated the alterations characteristic of acute Apc loss are 
unaffected by additional loss of Lect2 (data shown are means ± S.D. of a minimum 
of 25 whole crypts from four independent experiments; Mann-Whitney *P < 0.05). 
Lect2 deficiency doesn’t alter expression of Wnt target genes (E) in the normal or 
Apc deficient small intestine. 
 
Figure 4: Loss of Lect2 alters the circulating concentration of key cytokines. 
ELISA analysis indicating a general decrease in circulating cytokines in serum from 
WT, AhcreApc+/fl and AhcreApc+/flLect2-/- at 55 d.p.i. for IL-10 (A), IL-17 (B), TNF-
alpha (C), IL-6 (D), Ifn (e), IL-4 (f), and IL-2 (G) (data shown are means ± S.D. of a 




Figure 5: Loss of Lect2 significantly up-regulates the CD4+ T cell population. 
(A-F) FACS analysis of mononuclear cells in liver and spleen from 
AhCre+Apcfl/+Lect2+/+ and AhCre+Apcfl/+Lect2-/- at 55d.p.i. The graphs represent the 
percentage of cells gated on CD45+ cells in either the liver (A-C) or the spleen (D-F) 
(data shown are means ± S.D. of a minimum of four independent experiment, all N=5 
Mann-Whitney *, P < 0.05). 
 
Figure 6: Lect2 regulates the expression of lineage-specification factors in the 
spleen. (A) qRT-PCR analysis of tissue expression of key transcription factors  in 
AhCre+Apc+/flxLect2+/+ (white bars) and AhCre+Apc+/flxLect2-/- (grey bars) compared to 
the normal splenic tissue from AhCre+Apc+/+Lect2+/+ mice (black bars) (data shown is 
in terms of dC(t) values used to calculate ddC(t) fold change) (Mann-Whitney *, P < 
0.05. Quantification of CD4+ (B) and CD8+ (C) cells in small intestinal polyps.  
Quantification of CD4+(D) and CD8+(E) cells indicates an increase in the density of 
CD8+ cells inT1 stage tumours from Apc+/minLect2-/- mice compared to control 
Apc+/min mice (all N=4; *Mann-Whitney P>0.05). Quantification of CD3+FoxP3+ Treg 
cells in spleen and small intestine (F). 
 
Supplementary Figure 1:  The intestinal tumour resistant ApcMin/+Mbd2-/-mice 
are unaffected by the additional loss of Lect2.  (A) Survival curve indicating no 
difference in lifespan (A) or tumour burden (B) at death between ApcMin/+Mbd2-/- 




Supplementary Figure 2: No effect of Lect2 deficiency on the Wnt activated 
intestine. Lect2 deficiency doesn’t alter Paneth cell localization (B) in the in the 
normal or Apc deficient small intestine 
 
Supplementary Figure 3: Analysis of lymphocyte populations in Lect2 deficient 
mice.  Flow cytometry analysis indicated no alteration to the populations of cells 
indicated in each panel upon loss of Lect2 in Apc+/fl intestine at 55 d.p.i.. 
 
 






